-
Journal of Clinical Oncology : Official... Sep 1989One thousand four hundred sixty patients with 2,590 patient-years of follow-up were treated on 15 protocols for metastatic breast cancer with dibromodulcitol... (Review)
Review
One thousand four hundred sixty patients with 2,590 patient-years of follow-up were treated on 15 protocols for metastatic breast cancer with dibromodulcitol (mitolactol; DBD)-containing regimens since 1976. Twenty-three patients developed myelodysplastic syndrome (MDS) and/or acute nonlymphocytic leukemia (ANLL). The overall risk of developing MDS or ANLL per person is 1.6%. In patients who had received more than 16,000 mg of DBD the risk per person is 6%, and in the high-dose subsets of patients who received no prior radiation or alkylator therapy, it is 7.9%. The risk per person increases to a maximum by 30 to 36 months (5.3%). The high risk was seen despite a study population of metastatic breast cancer patients with a median survival of 16 months. This analysis strongly suggests that DBD is one of the most potent of the reported leukemogenic-inducing agents. Further use of this drug in both the adjuvant and metastatic situation should be reconsidered.
Topics: Adult; Aged; Breast Neoplasms; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitolactol; Myelodysplastic Syndromes; Risk
PubMed: 2671284
DOI: 10.1200/JCO.1989.7.9.1252 -
Ceskoslovenska Otolaryngologie Mar 1989The authors deal in their paper with the problem of nondifferentiated carcinoma in childhood. They draw attention to data in the literature which report an incidence of...
The authors deal in their paper with the problem of nondifferentiated carcinoma in childhood. They draw attention to data in the literature which report an incidence of 1-15% and compare with these data their own experience according to which in 158 patients with carcinoma of the nasopharynx there were seven children. They emphasize the inexpressive character of symptoms and thus the relatively long time which elapses before causal anti-tumourous treatment is started in child patients. They emphasize the importance of a uniform diagnostic protocol where they accentuate the directoscopy of the Rosenmüller fossa, tympanometry, computed tomography and draw attention to the advantages of EBV serology and mapping according to the HLA system. As far as treatment is concerned, they recommend radiotherapy, supplemented by adjuvant administration of the transfer factor and Mitolactol. In the conclusion the authors emphasize the necessity of team work to ensure correct interpretation of results from the diagnostic sphere and to ensure treatment in the initial stages when therapy gives the most permanent results.
Topics: Adolescent; Carcinoma; Child; Child, Preschool; Female; Humans; Male; Nasopharyngeal Neoplasms
PubMed: 2731256
DOI: No ID Found -
European Journal of Cancer & Clinical... Jan 1989
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Female; Humans; Idarubicin; Middle Aged; Mitolactol; Neutropenia; Thrombocytopenia
PubMed: 2920761
DOI: 10.1016/0277-5379(89)90063-1 -
American Journal of Clinical Oncology Dec 1988Twenty-two patients with metastatic melanoma were treated with a chemotherapy regimen consisting of two cycles of induction therapy with vinblastine, bleomycin, and...
A phase II trial of vinblastine, bleomycin, and cisplatin induction followed by dacarbazine and dibromodulcitol maintenance in the treatment of metastatic melanoma. A follow-up study of twenty-two patients.
Twenty-two patients with metastatic melanoma were treated with a chemotherapy regimen consisting of two cycles of induction therapy with vinblastine, bleomycin, and cisplatin, followed by maintenance therapy with dacarbazine and dibromodulcitol. A 17% response rate was noted in this patient group, with a median survival of 40 weeks. Objective responses were limited to cutaneous, nodal, pulmonary, and one adrenal site of metastatic disease. Toxicity was acceptable and was limited to myelosuppression and nausea with emesis. Further study appears warranted to define the optimal treatment plan for metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Dacarbazine; Drug Evaluation; Female; Follow-Up Studies; Humans; Male; Melanoma; Middle Aged; Mitolactol; Vinblastine
PubMed: 2461074
DOI: 10.1097/00000421-198812000-00016 -
Cancer Oct 1988Effects of preoperative chemotherapy with three courses of a combination of bleomycin, vincristine, mitolactol, prednisone, and methotrexate, with a leucovorin rescue,...
Effects of preoperative chemotherapy with three courses of a combination of bleomycin, vincristine, mitolactol, prednisone, and methotrexate, with a leucovorin rescue, followed by surgery were studied in 43 patients with advanced squamous cell carcinoma of the oral region. Before chemotherapy 34 patients (79%) had Stage III or IV carcinomas whereas nine patients had Stage II lesions. The clinical response was very encouraging: 20 patients (46%) achieved a clinical complete response and 23 patients (54%) were judged as partial responders. Side effects of this chemotherapy were minimal and reversible. Between 15 and 22 days after the last course of chemotherapy patients went to surgery. Wound healing complications did not occur. The surgical specimens were tested microscopically. The microphotographs showed small tumor rests with giant cells bordered by fibrous scar tissue and separated from the healthy tissues. With a median follow-up of 36 months (range, 21-58 months) 74% of patients are alive and 70% remain disease-free. Eleven patients died but only five (11%) because of the failure of therapy. This combined therapy appears both safe and promising treatment for advanced squamous cell carcinomas of the oral cavity. A further follow-up study needed to confirm the promising 5-year results.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Follow-Up Studies; Humans; Middle Aged; Mouth Neoplasms; Neoplasm Staging; Remission Induction
PubMed: 3416268
DOI: 10.1002/1097-0142(19881001)62:7<1267::aid-cncr2820620704>3.0.co;2-g -
Cancer May 1988One hundred consecutive patients with cerebral metastases from malignant melanoma were studied in relation to survival from the time of diagnosis of central nervous...
One hundred consecutive patients with cerebral metastases from malignant melanoma were studied in relation to survival from the time of diagnosis of central nervous system (CNS) involvement, response to treatment, characteristics of their primary lesion, and the course of the disease from initial diagnosis to the development of intracranial tumor. After treatment, clinical and investigational evidence of objective regression of cerebral lesions was demonstrable in ten patients who survived with a median of 11.5 months from diagnosis of CNS involvement. In 11 additional patients, CNS disease remained clinically stable for a median period of 7 months. Median survival for the entire group of 100 patients was 2.5 months. However, eight patients (8%) survived longer than 1 year from the time of diagnosis of cerebral metastases, four of whom (4%) survived longer than 2 years; the longest survivor being disease-free and incomplete neurologic remission at more than 82 months. Patients with malignant melanoma metastatic to the brain should be informed of the therapeutic options available for their disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dexamethasone; Evaluation Studies as Topic; Humans; Hydroxyurea; Lomustine; London; Melanoma; Mitolactol; Prognosis; Radioisotope Teletherapy
PubMed: 3355984
DOI: 10.1002/1097-0142(19880501)61:9<1926::aid-cncr2820610934>3.0.co;2-i -
Cancer Chemotherapy and Pharmacology 1988The human tumor stem-cell assay was used to investigate the in vitro chemosensitivity of 27 evaluable samples to cisplatin and its analogues, iproplatin and carboplatin,... (Comparative Study)
Comparative Study
The human tumor stem-cell assay was used to investigate the in vitro chemosensitivity of 27 evaluable samples to cisplatin and its analogues, iproplatin and carboplatin, as well as to BCNU, teniposide, vindesine, and dibromodulcitol. All agents exhibited some antitumor activity with the exception of dibromodulcitol (zero response out of 19 evaluable samples). Vindesine, BCNU, and carboplatin were the three most active compounds, with response rates of 29%, 23%, and 22%, respectively. There was a lack of complete cross-resistance between carboplatin and cisplatin as well as between carboplatin and BCNU. Our data suggest that clinical studies with carboplatin and combinations of vindesine plus cisplatin and its analogues may be worthwhile.
Topics: Brain Neoplasms; Carboplatin; Carmustine; Cisplatin; Colony-Forming Units Assay; Drug Resistance; Humans; Mitolactol; Organoplatinum Compounds; Teniposide; Tumor Stem Cell Assay; Vindesine
PubMed: 3293841
DOI: 10.1007/BF00254187 -
Neoplasma 1988Dibromdulcitol containing modified MOPP chemotherapeutic regimen plus radiotherapy were used in 58 children with Stage I-IV Hodgkin's disease diagnosed between 1975 and...
Dibromdulcitol containing modified MOPP chemotherapeutic regimen plus radiotherapy were used in 58 children with Stage I-IV Hodgkin's disease diagnosed between 1975 and 1985 in Hungary. A remission rate of 93.1% and a 5-year relapse-free survival of 89% was observed. Some latent hyperthyreoidism as late effect of the therapy, no growth disturbances and no adverse gonadal effects were seen until now.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Hodgkin Disease; Humans; Male; Mechlorethamine; Mitolactol; Prednisone; Procarbazine; Radiography; Vincristine
PubMed: 3216934
DOI: No ID Found -
Neoplasma 1988Effects of preoperative chemotherapy with three courses of a combination of bleomycin, vincristine, mitolactol, prednisolone and methotrexate, with a leucovorin rescue,...
An effective combined therapy for advanced squamous cell carcinoma of the oral cavity: preoperative BVMM (bleomycin, vincristine, mitolactol plus methotrexate and leucovorin) chemotherapy followed by surgery.
Effects of preoperative chemotherapy with three courses of a combination of bleomycin, vincristine, mitolactol, prednisolone and methotrexate, with a leucovorin rescue, followed by surgery, were studied in 43 patients with advanced squamous cell carcinoma of the oral region. Prior to chemotherapy 32 patients (74%) had advanced T3 or T4 carcinomas whilst 11 patients had T2 lesions. All patients responded clinically to preoperative chemotherapy: 20 patients (46%) achieved clinically complete remission and 23 patients (54%) were judged as partial responders. Sideeffects of this combination chemotherapy were minimal and reversible. Between 15 and 22 days after the last course of chemotherapy the patients underwent surgery, after which 100% were judged to be disease-free. Wound healing complications did not occur. With a median follow-up of 23 months (range 8-45 months), 81% of patients are alive and 79% remain disease free. This combined therapy appears both safe and effective for advanced squamous cell carcinomas of the oral cavity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Mouth Neoplasms
PubMed: 3216933
DOI: No ID Found -
Pediatric Hematology and Oncology 1988
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Female; Humans; Infant; Male; Mitolactol; Neoplasm Recurrence, Local; Pilot Projects; Procarbazine; Vincristine
PubMed: 3152960
DOI: 10.3109/08880018809031265